FREMONT, Calif., Jan. 4, 2016 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused
on gastrointestinal and cardio-renal diseases, today announced that
Paul Korner, MD, MBA, joined the
Company in a newly created position as Executive Vice President and
Chief Medical Officer. Dr. Korner brings extensive medical
affairs and clinical development experience to Ardelyx, having
contributed to the FDA approvals of numerous drugs and devices that
have generated several billion dollars in global sales. His
appointment is effective immediately.
![Ardelyx logo Ardelyx logo](http://photos.prnewswire.com/prnvar/20140619/119451)
"We are excited to have Paul join Ardelyx at a time when the
Company is advancing several mid- to late-stage clinical programs
for IBS-C, hyperphosphatemia and hyperkalemia and are building a
team as we prepare for commercialization," said Mike Raab, President and Chief Executive Officer
of Ardelyx. "Paul is a seasoned pharmaceutical executive with an
extensive clinical development and medical affairs background, who
has participated in many programs leading to product approvals from
the FDA and other global regulatory agencies. We are eager to have
him join the team at this juncture in the Company's evolution to
help Ardelyx succeed in its goal of becoming a fully integrated,
leading gastroenterology and cardio-renal company."
Dr. Korner joins Ardelyx with 17-years of pharmaceutical
industry experience, having served in various leadership positions
of increased responsibility with several global companies. Over the
past seven years, he served as President, Ferring International
Pharmascience Center U.S. Inc. (FIPCUS) & Senior Vice
President, U.S. Development for Ferring Pharmaceuticals where he
built and led Ferring's U.S. clinical development subsidiary
responsible for gastroenterology, reproductive health, orthopedics
and urology therapeutic areas and was a member of senior global R
& D management. Dr. Korner joined Ferring in 2008 as Vice
President, Medical Affairs, responsible for pharmacovigilance,
medical information and medical staff supporting Ferring's marketed
products.
Prior to joining Ferring, Dr. Korner was Vice President of
Medical Affairs, Female Health at Bayer HealthCare
Pharmaceuticals, where his group supported the
U.S. business unit and Phase 2 to Phase 4 development
projects. He also served as Senior Director of Clinical
Research and Development, Women's Health
and Musculoskeletal Bone Repair for Wyeth Research and as
Director, Medical Affairs - GI and Women's Health for Solvay
Pharmaceuticals.
Dr. Korner is a board-certified obstetrician and gynecologist.
He received his MD from Loyola
University, Stritch School of Medicine in Illinois. He also holds an MBA from the
Michael J. Coles College of
Business at Kennesaw State University
in Georgia.
"I am thrilled to join Ardelyx at such a transformational stage
of the company, and I look forward to helping advance its novel GI
and cardio-renal therapies that have the potential to address high
unmet medical needs and improve patient lives," stated Dr.
Korner.
About Ardelyx, Inc.
Ardelyx is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
innovative, minimally-systemic, small molecule therapeutics that
work exclusively in the gastrointestinal tract to treat
gastrointestinal and cardio-renal diseases. Ardelyx has developed a
proprietary drug discovery and design platform enabling it, in a
rapid and cost-efficient manner, to discover and design novel drug
candidates. Utilizing this platform, Ardelyx has discovered and
designed tenapanor, which it is evaluating for the treatment of
constipation-predominant irritable bowel syndrome (IBS-C) and for
the control of hyperphosphatemia in CKD patients on dialysis. In
addition to tenapanor, Ardelyx is developing RDX022, a non-absorbed
polymer for the treatment of hyperkalemia, or high potassium, in
kidney and heart disease patients. Ardelyx is also advancing
several research programs focused in gastrointestinal and
cardio-renal diseases. Ardelyx is located in Fremont,
California. For more information,
please visit Ardelyx's website
at www.ardelyx.com.
Logo - http://photos.prnewswire.com/prnh/20140619/119451
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ardelyx-strengthens-executive-leadership-team-with-the-appointment-of-paul-korner-md-mba-as-executive-vice-president-and-chief-medical-officer-300198449.html
SOURCE Ardelyx